Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.81
$2.24
52-Week Range
N/A
Volume
2,579 shs
Average Volume
162,968 shs
Market Capitalization
$8.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REXN Stock News Headlines

Aurinia Pharmaceuticals Inc AUPH
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Rexahn: Holes Galore in Serdaxin Data
See More Headlines

REXN Stock Analysis - Frequently Asked Questions

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.34.

Rexahn Pharmaceuticals's stock reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
8/07/2019
Today
5/24/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REXN
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8.11 million
Optionable
Optionable
Beta
0.98
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:REXN) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners